Phase I and II enzyme polymorphisms as risk factors for Barrett's esophagus and esophageal adenocarcinoma: A systematic review and meta-analysis

Diseases of the Esophagus

Volumn 22, Issue 7, 2009, Pages 571-587

  Bull, L M ^a   White, D L ^a   Bray, M ^a   Nurgalieva, Z ^a   El Serag, H B ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Barrett's esophagus; Epidemiology; Esophageal adenocarcinoma; Genetic association; Gst; Single nucleotide polymorphism (SNP)

Indexed keywords

ADENOCARCINOMA; BARRETT ESOPHAGUS; CASE CONTROL STUDY; ENZYMOLOGY; ESOPHAGUS TUMOR; GENETIC PREDISPOSITION; GENETICS; HUMAN; META ANALYSIS; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CASE-CONTROL STUDIES; ESOPHAGEAL NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 73949119716     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2009.00947.x     Document Type: Review

References (92)

1. Blot W J, Devesa S S, Kneller R W, Fraumeni J F Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265(10): 1287-9.
2. Devesa S S, Blot W J, Fraumeni J F Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83(10): 2049-53.
3. Younes M, Henson D E, Ertan A, Miller C C. Incidence and survival trends of esophageal carcinoma in the United States: racial and gender differences by histological type. Scand J Gastroenterol 2002; 37(12): 1359-65.
4. Gerson L B, Shetler K, Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 2002; 123(2): 461-7.
5. Rex D K, Cummings O W, Shaw M et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003; 125(6): 1670-7.
6. Streitz J M Jr. Barrett's esophagus and esophageal cancer. Chest Surg Clin N Am 1994; 4(2): 227-40.
7. Vallbohmer D, Lenz H J. Predictive and prognostic molecular markers in outcome of esophageal cancer. Dis Esophagus 2006; 19(6): 425-32.
8. Hiyama T, Yoshihara M, Tanaka S, Chayama K. Genetic polymorphisms and esophageal cancer risk. Int J Cancer 2007; 121(8): 1643-58.
9. Yang C X, MatsuoK, Wang ZM, TajimaK. Phase I/II enzyme gene polymorphisms and esophageal cancer risk: a metaanalysis of the literature. World J Gastroenterol 2005; 11(17): 2531-8.
10. Stroup D F, Berlin J A, Morton S C et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) Group. JAMA 2000; 283(15): 2008-12.
11. Abbas A, Delvinquiere K, LechevrelMet al. GSTM1, GSTT1, GSTP1 and CYP1A1 genetic polymorphisms and susceptibility to esophageal cancer in a French population: different pattern of squamous cell carcinoma and adenocarcinoma. World J Gastroenterol 2004; 10(23): 3389-93.
12. Casson A G, Zheng Z, Chiasson D et al. Associations between genetic polymorphisms of Phase I and II metabolizing enzymes, p53 and susceptibility to esophageal adenocarcinoma. Cancer Detect Prev 2003; 27(2): 139-46.
13. Casson A G, Zheng Z, Porter G A, Guernsey D L. Genetic polymorphisms of microsomal epoxide hydroxylase and glutathione S-transferases M1, T1 and P1, interactions with smoking, and risk for esophageal (Barrett) adenocarcinoma. Cancer Detect Prev 2006; 30(5): 423-31.
14. di Martino E, Hardie L J, Wild C P et al. The NAD-(P)H:quinone oxidoreductase I C609T polymorphism modifies the risk of Barrett esophagus and esophageal adenocarcinoma. Genet Med 2007; 9(6): 341-7.
15. Jain M, Kumar S, Rastogi N et al. GSTT1, GSTM1 and GSTP1 genetic polymorphisms and interaction with tobacco, alcohol and occupational exposure in esophageal cancer patients from North India. Cancer Lett 2006; 242(1): 60-7.
16. Jain M, Kumar S, Lal P, Tiwari A, Ghoshal UC, Mittal B. Role of GSTM3 polymorphism in the risk of developing esophageal cancer. Cancer Epidemiol Biomarkers Prev 2007; 16(1): 178-81.
17. Kala Z, Dolina J, Marek F, Izakovicova H L. Polymorphisms of glutathione S-transferase M1, T1 and P1 in patients with reflux esophagitis and Barrett's esophagus. J Hum Genet 2007;52(6): 527-34.
18. Murphy S J, Hughes A E, Patterson C C et al. A populationbased association study of SNPs of GSTP1, MnSOD, GPX2 and Barrett's esophagus and esophageal adenocarcinoma. Carcinogenesis 2007; 28(6): 1323-8.
19. Sarbia M, Bitzer M, Siegel D et al. Association between NAD(P)H: quinone oxidoreductase 1 (NQ01) inactivating C609T polymorphism and adenocarcinoma of the upper gastrointestinal tract. Int J Cancer 2003; 107(3): 381-6.
20. van Lieshout E M, Roelofs H M, Dekker S et al. Polymorphic expression of the glutathione S-transferase P1 gene and its susceptibility to Barrett's esophagus and esophageal carcinoma. Cancer Res 1999; 59(3): 586-9.
21. von Rahden B H, Stein H J, Langer R et al. C609T polymorphism of the NAD(P)H: quinone oxidoreductase I gene does not significantly affect susceptibility for esophageal adenocarcinoma. Int J Cancer 2005; 113(3): 506-8.
22. Wideroff L, Vaughan T L, Farin F M et al. GST, NAT1, CYP1A1 polymorphisms and risk of esophageal and gastric adenocarcinomas. Cancer Detect Prev 2007; 31(3): 233-6.
23. Gao C, Takezaki T, Wu J et al. Interaction between cytochrome P-450 2E1 polymorphisms and environmental factors with risk of esophageal and stomach cancers in Chinese. Cancer Epidemiol Biomarkers Prev 2002; 11(1): 29-34.
24. Gao CM, Toshiro T, Wu J Z et al. [A case-control study on the polymorphisms of methylenetetrahydrofolate reductase 1298A->C and susceptibility of esophageal cancer.] Zhonghua Liu Xing Bing Xue Za Zhi 2004; 25(4): 341-5.
25. Gao C M, Takezaki T, Wu J Z et al. Polymorphisms in thymidylate synthase and methylenetetrahydrofolate reductase genes and the susceptibility to esophageal and stomach cancer with smoking. Asian Pac J Cancer Prev 2004; 5(2): 133-8.
26. Huang Z G. [Meta-analysis on glutathione S-transferase M1 polymorphisms and the risk of esophageal cancer.] Zhonghua Liu Xing Bing Xue Za Zhi 2004; 25(10): 898-901.
27. Itoga S, Nomura F, Makino Y et al. Tandem repeat polymorphism of the CYP2E1 gene: an association study with esophageal cancer and lung cancer. Alcohol Clin Exp Res 2002; 26(Suppl 8): 15S-19S.
28. Li Y, Zhang J H, Guo W, Wang R, Wen D G, Wei L Z. [Polymorphism of NAD(P)H dehydrogenase (quinone) 1 (NQO1) C 609 T and risk of esophageal neoplasm.] Zhonghua Liu Xing Bing Xue Za Zhi 2004; 25(8): 731.
29. Nimura Y, Yokoyama S, Fujimori M et al. Genotyping of the CYP1A1 and GSTM1 genes in esophageal carcinoma patients with special reference to smoking. Cancer 1997; 80(5): 852-7.
30. Lin D X, Tang Y M, Peng Q, Lu S X, Ambrosone C B, Kadlubar F F. Susceptibility to esophageal cancer and genetic polymorphisms in glutathione S-transferases T1, P1, and M1 and cytochrome P450 2E1. Cancer Epidemiol Biomarkers Prev 1998; 7(11): 1013-18.
31. Wang A H, Sun C S, Li L S, Huang J Y, Chen Q S. Relationship of tobacco smoking CYP1A1 GSTM1 gene polymorphism and esophageal cancer in Xi'an. World J Gastroenterol 2002; 8(1): 49-53.
32. Gonzalez C A, Sala N, Capella G. Genetic susceptibility and gastric cancer risk. Int J Cancer 2002; 100(3): 249-60.
33. Bartsch H, Nair U, Risch A, Rojas M, Wikman H, Alexandrov K. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev 2000; 9(1): 3-28.
34. Leistner-Segal S, Kaspary A P, Lopez P, Pilger D A, Segal F. TP53 gene R72P polymorphism analysis in patients with Barrett esophagus. Cancer Genet Cytogenet 2006; 170(1): 76-7.
35. Higgins J P, Thompson S G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21(11): 1539-58.
36. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7(3): 177-88.
37. li-Osman F, Akande O, Antoun G, Mao J X, Buolamwini J. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem 1997; 272(15): 10004-12.
38. Ntais C, Polycarpou A, Ioannidis J P. Association of GSTM1, GSTT1, and GSTP1 gene polymorphisms with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2005; 14(1): 176-81.
39. Sundberg K, Johansson A S, Stenberg G et al. Differences in the catalytic efficiencies of allelic variants of glutathione transferase P1-1 towards carcinogenic diol epoxides of polycyclic aromatic hydrocarbons. Carcinogenesis 1998; 19(3): 433-6.
40. Voho A, Impivaara O, Jarvisalo J, Metsola K, Vainio H, Hirvonen A. Distribution of glutathione S-transferase M1, P1 and T1 genotypes in different age-groups of Finns without diagnosed cancer. Cancer Detect Prev 2006; 30(2): 144-51.
41. Smith C A, Smith G, Wolf C R. Genetic polymorphisms in xenobiotic metabolism. Eur J Cancer 1994; 30A (13): 1921-35.
42. Cascorbi I, Brockmoller J, Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 1996; 56(21): 4965-9.
43. Landi M T, Bertazzi P A, Shields P G et al. Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics 1994; 4(5): 242-6.
44. Crofts F, Taioli E, Trachman J et al. Functional significance of different human CYP1A1 genotypes. Carcinogenesis 1994; 15(12): 2961-3.
45. Garte S, Gaspari L, Alexandrie A K et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001; 10(12): 1239-48.
46. Oesch F, Schmassmann H. Species and organ specificity of the trans-stilbene oxide induced effects on epoxide hydratase and benzo(a)pyrene monooxygenase activity in rodents. Biochem Pharmacol 1979; 28(2): 171-6.
47. Omiecinski C J, Aicher L, Holubkov R, Checkoway H. Human peripheral lymphocytes as indicators of microsomal epoxide hydrolase activity in liver and lung. Pharmacogenetics 1993; 3(3): 150-8.
48. Seidegard J, Ekstrom G. The role of human glutathione transferases and epoxide hydrolases in the metabolism of xenobiotics. Environ Health Perspect 1997; 105(Suppl 4): 791-9.
49. Hassett C, Aicher L, Sidhu J S, Omiecinski C J. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet 1994; 3(3): 421-8.
50. Jourenkova-Mironova N, Mitrunen K, Bouchardy C, Dayer P, Benhamou S, Hirvonen A. High-activity microsomal epoxide hydrolase genotypes and the risk of oral, pharynx, and larynx cancers. Cancer Res 2000; 60(3): 534-6.
51. Lin Y C, Wu D C, Lee J M et al. The association between microsomal epoxide hydrolase genotypes and esophageal squamous-cell-carcinoma in Taiwan: interaction between areca chewing and smoking. Cancer Lett 2006; 237(2): 281-8.
52. Lee W J, Brennan P, Boffetta P et al. Microsomal epoxide hydrolase polymorphisms and lung cancer risk: a quantitative review. Biomarkers 2002; 7(3): 230-41.
53. Harrison D J, Hubbard A L, MacMillan J, Wyllie A H, Smith C A. Microsomal epoxide hydrolase gene polymorphism and susceptibility to colon cancer. Br J Cancer 1999; 79(1): 168-71.
54. Tiemersma EW, OmerRE, BunschotenAet al. Role of genetic polymorphism of glutathione-S-transferase T1 and microsomal epoxide hydrolase in aflatoxin-associated hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2001; 10(7): 785-91.
55. Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y. EPHX1 polymorphisms and the risk of lung cancer: a HuGE review. Epidemiology 2006; 17(1): 89-99.
56. Jaiswal AK. Regulation of genes encoding NAD(P)H: quinone oxidoreductases. Free Radic Biol Med 2000; 29(3-4): 254-62.
57. MontanoMM, Bianco N R, Deng H, Wittmann BM, Chaplin L C, Katzenellenbogen B S. Estrogen receptor regulation of quinone reductase in breast cancer: implications for estrogeninduced breast tumor growth and therapeutic uses of tamoxifen. Front Biosci 2005; 10: 1440-61.
58. Lyn-Cook B D, Yan-Sanders Y, Moore S, Taylor S, Word B, Hammons G J. Increased levels of NAD(P)H: quinone oxidoreductase 1 (NQO1) in pancreatic tissues from smokers and pancreatic adenocarcinomas: a potential biomarker of early damage in the pancreas. Cell Biol Toxicol 2006; 22(2): 73-80.
59. Lafuente M J, Casterad X, Trias M et al. NAD(P)H: quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors. Carcinogenesis 2000; 21(10): 1813-19.
60. Zhang J, Schulz W A, Li Y et al. Association of NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism with esophageal squamous cell carcinoma in a German Caucasian and a northern Chinese population. Carcinogenesis 2003; 24(5): 905-9.
61. Siegel D, McGuinness S M, Winski S L, Ross D. Genotypephenotype relationships in studies of a polymorphism in NAD(P)H: quinone oxidoreductase 1. Pharmacogenetics 1999; 9(1): 113-21.
62. Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y. NQO1, MPO, and the risk of lung cancer: a HuGE review. Genet Med 2005; 7(7): 463-78.
63. Kelsey K T, Ross D, Traver R D et al. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br J Cancer 1997; 76(7): 852-4.
64. Hein D W. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res 2002; 506-507: 65-77.
65. Zheng W, Deitz A C, Campbell D R et al. N-acetyltransferase 1 genetic polymorphism, cigarette smoking, well-done meat intake, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999; 8(3): 233-9.
66. Hickman D, Risch A, Buckle V et al. Chromosomal localization of human genes for arylamine N-acetyltransferase. Biochem J 1994; 297(Pt 3): 441-5.
67. Ebisawa T, Deguchi T. Structure and restriction fragment length polymorphism of genes for human liver arylamine N-acetyltransferases. Biochem Biophys Res Commun 1991; 177(3): 1252-7.
68. Bell D A, Badawi A F, Lang N P, Ilett K F, Kadlubar F F, Hirvonen A. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res 1995; 55(22): 5226-9.
69. Zenser T V, Lakshmi V M, Rustan T D et al. Human N-acetylation of benzidine: role of NAT1 and NAT2. Cancer Res 1996; 56(17): 3941-7.
70. Bruhn C, Brockmoller J, Cascorbi I, Roots I, Borchert H H. Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1). Biochem Pharmacol 1999; 58(11): 1759-64.
71. Yang M, Katoh T, Delongchamp R, Ozawa S, Kohshi K, Kawamoto T. Relationship between NAT1 genotype and phenotype in a Japanese population. Pharmacogenetics 2000; 10(3): 225-32.
72. Zhao B, Lee E J, Yeoh P N, Gong N H. Detection of mutations and polymorphism of N-acetyltransferase 1 gene in Indian, Malay and Chinese populations. Pharmacogenetics 1998; 8(4): 299-304.
73. Hayes J D, Pulford D J. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995; 30(6): 445-600.
74. Mannervik B, Awasthi Y C, Board P G et al. Nomenclature for human glutathione transferases. Biochem J 1992; 282(Pt 1): 305-6.
75. Benhamou S, LeeWJ, Alexandrie A K et al. Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. Carcinogenesis 2002; 23(8): 1343-50.
76. Hashibe M, Brennan P, Strange R C et al. Meta- and pooled analyses of GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes and risk of head and neck cancer. Cancer Epidemiol Biomarkers Prev 2003; 12(12): 1509-17.
77. Board P G. Biochemical genetics of glutathione-S-transferase in man. Am J Hum Genet 1981; 33(1): 36-43.
78. Wiebel F A, Dommermuth A, Thier R. The hereditary transmission of the glutathione transferase hGSTT1-1 conjugator phenotype in a large family. Pharmacogenetics 1999; 9(2): 251-6.
79. Gilliland F D, Li Y F, Saxon A, Az-Sanchez D. Effect of glutathione-S-transferase M1 and P1 genotypes on xenobiotic enhancement of allergic responses: randomised, placebo-controlled crossover study. Lancet 2004; 363(9403): 119-25.
80. Geisler S A, Olshan A F. GSTM1, GSTT1, and the risk of squamous cell carcinoma of the head and neck: a mini-HuGE review. Am J Epidemiol 2001; 154(2): 95-105.
81. Inskip A, Elexperu-Camiruaga J, Buxton N et al. Identification of polymorphism at the glutathione S-transferase, GSTM3 locus: evidence for linkage with GSTM1* Biochem J 1995; 312(Pt 3): 713-16.
82. Mohammadzadeh G S, Nasseri M S, Rasaee M J, Zaree A B, Mahmoodzadeh H, Allameh A. Measurement of glutathione S-transferase and its class-pi in plasma and tissue biopsies obtained after laparoscopy and endoscopy from subjects with esophagus and gastric cancer. Clin Biochem 2003; 36(4): 283-8.
83. Liu B, Fan Y J, Wang M L et al. Genetic polymorphisms in glutathione S-transferases T1, M1 and P1 and susceptibility to reflux esophagitis. Dis Esophagus 2006; 19(6): 477-81.
84. Lee J M, Lee Y C, Yang S Y et al. Genetic polymorphisms of p53 and GSTP1, but not NAT2, are associated with susceptibility to squamous-cell carcinoma of the esophagus. Int J Cancer 2000; 89(5): 458-64.
85. Morita S, Yano M, Tsujinaka T et al. Association between genetic polymorphisms of glutathione S-transferase P1 and N-acetyltransferase 2 and susceptibility to squamous-cell carcinoma of the esophagus. Int J Cancer 1998; 79(5): 517-20.
86. Zimniak P, Nanduri B, Pikula S et al. Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur J Biochem 1994; 224(3): 893-9.
87. Pandya U, Srivastava S K, Singhal S S et al. Activity of allelic variants of Pi class human glutathione S-transferase toward chlorambucil. Biochem Biophys Res Commun 2000; 278(1): 258-62.
88. Hand P A, Inskip A, Gilford J et al. Allelism at the glutathione S-transferase GSTM3 locus: interactions with GSTM1 and GSTT1 as risk factors for astrocytoma. Carcinogenesis 1996;17(9): 1919-22.
89. Ioannidis J P, Trikalinos T A. Early extreme contradictory estimates may appear in published research: the Proteus phenomenon in molecular genetics research and randomized trials. J Clin Epidemiol 2005; 58(6): 543-9.
90. Wright A F, Carothers A D, Pirastu M. Population choice in mapping genes for complex diseases. Nat Genet 1999; 23(4): 397-404.
91. Hattersley A T, McCarthy M I. What makes a good genetic association study? Lancet 2005; 366(9493): 1315-23.
92. Salanti G, Sanderson S, Higgins J P. Obstacles and opportunities in meta-analysis of genetic association studies. Genet Med 2005; 7(1): 13-20.